Approval · Notice of Compliance 17148 · 2015
ZOFRAN: Notice of Compliance 17148
Issued July 30, 2015
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 17148
- Date
- July 30, 2015
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Transfer of Drug Identification Numbers
- Therapeutic class
- Antiemetic (5-HT3 receptor antagonist)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZOFRAN | 02213567 | Cancelled Post Market |
| ZOFRAN | 02213575 | Cancelled Post Market |
| ZOFRAN | 02213745 | Cancelled Post Market |
| ZOFRAN | 02229639 | Cancelled Post Market |
| ZOFRAN ODT | 02239372 | Dormant |
| ZOFRAN ODT | 02239373 | Dormant |
Medicinal ingredients
- ONDANSETRON HYDROCHLORIDE DIHYDRATE 4 MG per TAB
- ONDANSETRON HYDROCHLORIDE DIHYDRATE 8 MG per TAB
- ONDANSETRON HYDROCHLORIDE DIHYDRATE 2 MG per ML
- ONDANSETRON HYDROCHLORIDE DIHYDRATE 4 MG per 5ML
- ONDANSETRON 4 MG per TAB
- ONDANSETRON 8 MG per TAB